Identification

Name
Milrinone
Accession Number
DB00235  (APRD00010)
Type
Small Molecule
Groups
Approved
Description

A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the ionotropic potency of amrinone. [PubChem]

Structure
Thumb
Synonyms
  • 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile
  • Milrinona
  • Milrinone
  • Milrinonum
External IDs
WIN 47,203-2
Product Ingredients
IngredientUNIICASInChI Key
Milrinone Lactate9K8XR81MO8100286-97-3VWUPWEAFIOQCGF-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Milrinone InjectionSolution1 mgIntravenousTeva2003-05-252015-07-22Canada
Milrinone Lactate InjectionSolution1.0 mgIntravenousSandoz Canada Incorporated2003-06-25Not applicableCanada
Milrinone Lactate InjectionSolution1 mgIntravenousFresenius Kabi2003-07-03Not applicableCanada
Milrinone Lactate InjectionSolution1 mgIntravenousSterimax IncNot applicableNot applicableCanada
Milrinone Lactate InjectionSolution1 mgIntravenousAuro Pharma IncNot applicableNot applicableCanada
Milrinone Lactate InjectionSolution1 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Primacor Injection 1mg/mlSolution1 mgIntravenousSanofi Synthelabo1995-12-312005-08-01Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-milrinone InjectableSolution1.0 mgIntravenousApotex Corporation2005-07-292013-08-02Canada
Milrinone LactateInjection1 mg/mLIntravenousWest Ward Pharmaceutical2002-05-28Not applicableUs
Milrinone LactateInjection, solution10 mg/10mLIntravenousWest Ward Pharmaceutical2010-12-03Not applicableUs
Milrinone LactateInjection1 mg/mLIntravenousGland Pharma Limited2017-07-28Not applicableUs
Milrinone LactateInjection, solution1 mg/mLIntravenousHospira, Inc.2014-09-03Not applicableUs
Milrinone LactateInjection, solution20 mg/20mLIntravenousWest Ward Pharmaceutical2010-12-03Not applicableUs
Milrinone LactateInjection1 mg/mLIntravenousWest Ward Pharmaceutical2002-05-28Not applicableUs
Milrinone LactateInjection, solution1 mg/mLIntravenousFresenius Kabi2002-08-01Not applicableUs
Milrinone LactateInjection, solution50 mg/50mLIntravenousWest Ward Pharmaceutical2010-12-03Not applicableUs
Milrinone LactateInjection, solution200 ug/mLIntravenousHospira, Inc.2002-05-28Not applicableUs
International/Other Brands
Corotrop / Corotrope / Milrila / Primacor
Categories
UNII
JU9YAX04C7
CAS number
78415-72-2
Weight
Average: 211.2194
Monoisotopic: 211.074561925
Chemical Formula
C12H9N3O
InChI Key
PZRHRDRVRGEVNW-UHFFFAOYSA-N
InChI
InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)
IUPAC Name
6-methyl-2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridine-3-carbonitrile
SMILES
CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1

Pharmacology

Indication

Indicated for the treatment of congestive heart failure.

Structured Indications
Pharmacodynamics

Milrinone, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.

Mechanism of action

Milrinone inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, Milrinone also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity.

TargetActionsOrganism
AcGMP-inhibited 3',5'-cyclic phosphodiesterase A
inhibitor
Human
Absorption

Milrinone is rapidly and almost completely absorbed after oral administration. Bioavailability is 92% (in healthy volunteers).

Volume of distribution
  • 0.38 liters/kg [intravenous injections of 12.5 mcg/kg to 125 mcg/kg to congestive heart failure patients]
  • 0.45 liters/kg [intravenous infusions of 0.20 mcg/kg/min to 0.70 mcg/kg/min to congestive heart failure patients]
Protein binding

70 to 80%

Metabolism

There are five metabolites but the O-glucuronide represents the major pathway of biotransformation.

Route of elimination

The primary route of excretion of milrinone in man is via the urine.

Half life

2.3 hours

Clearance
  • 0.13 L/kg/hr [congestive heart failure patients, following IV injections of 12.5 mcg/kg to 125 mcg/kg]
  • 0.14 L/kg/hr [congestive heart failure patients, following infusions of 0.2 mcg/kg/min to 0.7 mcg/kg/min]
Toxicity

LD50 = 0.3 mg/L in rats

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabMilrinone may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolMilrinone may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Milrinone is combined with Acetylsalicylic acid.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Milrinone is combined with Aloxiprin.Experimental
AlprostadilMilrinone may increase the antiplatelet activities of Alprostadil.Approved, Investigational
AlteplaseMilrinone may increase the anticoagulant activities of Alteplase.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Milrinone is combined with Aminosalicylic Acid.Approved
AnagrelideMilrinone may increase the anticoagulant activities of Anagrelide.Approved
AncrodMilrinone may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideMilrinone may increase the antiplatelet activities of Andrographolide.Investigational
AnistreplaseMilrinone may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanMilrinone may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Milrinone is combined with Apixaban.Approved
ArdeparinMilrinone may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanMilrinone may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinMilrinone may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineMilrinone may increase the antiplatelet activities of Azelastine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Milrinone is combined with Balsalazide.Approved, Investigational
BatroxobinMilrinone may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminMilrinone may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinMilrinone may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BeraprostMilrinone may increase the anticoagulant activities of Beraprost.Investigational
BivalirudinMilrinone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseMilrinone may increase the anticoagulant activities of Brinase.Experimental
BuflomedilMilrinone may increase the antiplatelet activities of Buflomedil.Experimental
ButylphthalideMilrinone may increase the antiplatelet activities of Butylphthalide.Investigational
CangrelorMilrinone may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabMilrinone may increase the anticoagulant activities of Caplacizumab.Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Milrinone is combined with Carbaspirin calcium.Experimental, Investigational
CertoparinMilrinone may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolMilrinone may increase the anticoagulant activities of Cilostazol.Approved
Citric AcidMilrinone may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelMilrinone may increase the anticoagulant activities of Clopidogrel.Approved
CloricromenMilrinone may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneMilrinone may increase the anticoagulant activities of Clorindione.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Milrinone is combined with Collagenase clostridium histolyticum.Approved, Investigational
Dabigatran etexilateMilrinone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMilrinone may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMilrinone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanMilrinone may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Milrinone.Approved, Investigational
DefibrotideMilrinone may increase the anticoagulant activities of Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Milrinone is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Milrinone is combined with Dersalazine.Investigational
DesirudinMilrinone may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseMilrinone may increase the anticoagulant activities of Desmoteplase.Investigational
DextranMilrinone may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Milrinone may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Milrinone may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Milrinone may increase the anticoagulant activities of Dextran 75.Approved
DicoumarolMilrinone may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Milrinone is combined with Diflunisal.Approved
DiphenadioneMilrinone may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleMilrinone may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleMilrinone may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaMilrinone may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidMilrinone may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMilrinone may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinMilrinone may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineMilrinone may increase the antiplatelet activities of Epinastine.Approved, Investigational
EplivanserinMilrinone may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineMilrinone may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Milrinone.Approved
EptifibatideMilrinone may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
Ethyl biscoumacetateMilrinone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidMilrinone may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinMilrinone may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneMilrinone may increase the anticoagulant activities of Fluindione.Investigational
FondaparinuxMilrinone may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMilrinone may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateMilrinone may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Milrinone.Approved
GuacetisalThe risk or severity of adverse effects can be increased when Milrinone is combined with Guacetisal.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Milrinone is combined with Hemoglobin crosfumaril.Experimental
HeparinMilrinone may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineMilrinone may increase the anticoagulant activities of Higenamine.Investigational
HydroxytyrosolMilrinone may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Milrinone is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Milrinone.Approved
IbudilastMilrinone may increase the antiplatelet activities of Ibudilast.Approved, Investigational
Icosapent ethylMilrinone may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdraparinuxMilrinone may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilMilrinone may increase the antiplatelet activities of Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanMilrinone may increase the antiplatelet activities of Ifetroban.Investigational
IloprostIloprost may increase the antiplatelet activities of Milrinone.Approved, Investigational
IndobufenMilrinone may increase the anticoagulant activities of Indobufen.Investigational
KetanserinMilrinone may increase the antiplatelet activities of Ketanserin.Investigational
LepirudinMilrinone may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanMilrinone may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostLimaprost may increase the antiplatelet activities of Milrinone.Approved, Investigational
LinsidomineMilrinone may increase the antiplatelet activities of Linsidomine.Experimental
MelagatranMilrinone may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Milrinone is combined with Mesalazine.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Milrinone is combined with Methyl salicylate.Approved, Vet Approved
NadroparinMilrinone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMilrinone may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilMilrinone may increase the antiplatelet activities of Naftopidil.Investigational
NimesulideMilrinone may increase the antiplatelet activities of Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Milrinone is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Milrinone is combined with Obinutuzumab.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Milrinone is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Milrinone.Approved, Nutraceutical
OtamixabanMilrinone may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelMilrinone may increase the anticoagulant activities of Ozagrel.Investigational
ParnaparinMilrinone may increase the anticoagulant activities of Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateMilrinone may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Milrinone.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Milrinone.Approved, Investigational
PhenindioneMilrinone may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMilrinone may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PicotamideMilrinone may increase the anticoagulant activities of Picotamide.Experimental
PrasugrelMilrinone may increase the anticoagulant activities of Prasugrel.Approved
Protein CMilrinone may increase the anticoagulant activities of Protein C.Approved
Protein S humanMilrinone may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMilrinone may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanMilrinone may increase the antiplatelet activities of Ramatroban.Investigational
RelcovaptanMilrinone may increase the antiplatelet activities of Relcovaptan.Investigational
ResveratrolMilrinone may increase the antiplatelet activities of Resveratrol.Approved, Experimental, Investigational
ReteplaseMilrinone may increase the anticoagulant activities of Reteplase.Approved
ReviparinMilrinone may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelMilrinone may increase the antiplatelet activities of Ridogrel.Approved
RiociguatMilrinone may increase the hypotensive activities of Riociguat.Approved
RivaroxabanMilrinone may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneMilrinone may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Milrinone is combined with Salicylic acid.Approved, Vet Approved
SarpogrelateMilrinone may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseMilrinone may increase the anticoagulant activities of Saruplase.Experimental
SelexipagMilrinone may increase the anticoagulant activities of Selexipag.Approved
SevofluraneMilrinone may increase the antiplatelet activities of Sevoflurane.Approved, Vet Approved
SRT501Milrinone may increase the antiplatelet activities of SRT501.Investigational
StreptokinaseMilrinone may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulodexideMilrinone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseMilrinone may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneMilrinone may increase the antiplatelet activities of Tesmilifene.Investigational
TicagrelorMilrinone may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineMilrinone may increase the anticoagulant activities of Ticlopidine.Approved
TinzaparinMilrinone may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolMilrinone may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Milrinone.Approved, Investigational
TirofibanMilrinone may increase the anticoagulant activities of Tirofiban.Approved
TositumomabThe risk or severity of adverse effects can be increased when Milrinone is combined with Tositumomab.Approved, Investigational
TranilastMilrinone may increase the antiplatelet activities of Tranilast.Approved, Investigational
TrapidilMilrinone may increase the antiplatelet activities of Trapidil.Approved
TreprostinilTreprostinil may increase the antiplatelet activities of Milrinone.Approved, Investigational
TriflusalMilrinone may increase the anticoagulant activities of Triflusal.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Milrinone is combined with Trolamine salicylate.Approved
TroxerutinMilrinone may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseMilrinone may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Milrinone.Approved, Nutraceutical, Vet Approved
VorapaxarMilrinone may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinMilrinone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMilrinone may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14380
KEGG Drug
D00417
KEGG Compound
C07224
PubChem Compound
4197
PubChem Substance
46507838
ChemSpider
4052
BindingDB
15296
ChEBI
50693
ChEMBL
CHEMBL189
Therapeutic Targets Database
DAP000150
PharmGKB
PA164749171
HET
MIL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Milrinone
ATC Codes
C01CE02 — Milrinone
AHFS Codes
  • 24:04.08 — Cardiotonic Agents
PDB Entries
1tlm
FDA label
Download (491 KB)
MSDS
Download (34.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentEnd Stage Heart Disease / Right Ventricular Dysfunction1
1, 2Active Not RecruitingTreatmentHeart Failure, Unspecified1
1, 2CompletedTreatmentHealthy Volunteers / Heart Failure, Unspecified1
1, 2CompletedTreatmentLow Cardiac Output Syndrome1
1, 2CompletedTreatmentPulmonary Hypertension (PH)1
1, 2WithdrawnTreatmentMyocardial Reperfusion Injury1
2CompletedPreventionDefect, Congenital Heart1
2CompletedPreventionPulmonary Hypertension (PH)1
2CompletedTreatmentCoronary Artery Disease / Pulmonary Hypertension (PH) / Valvular Insufficiency / Valvular Stenosis1
2Not Yet RecruitingTreatmentHeart Failure, Unspecified / Prophylaxis of cardiomyopathy1
2RecruitingTreatmentCardiorenal Syndrome1
2RecruitingTreatmentCerebral Vasospasm1
2RecruitingTreatmentCongenital Diaphragmatic Hernias / Hypoplasia, Pulmonary / Hypoxemic Respiratory Failure / Persistent Pulmonary Hypertension of the Newborn1
2RecruitingTreatmentCongenital Heart Disease (CHD)1
2TerminatedTreatmentHeart Defects,Congenital1
2Unknown StatusTreatmentLow Cardiac Output Syndrome1
3CompletedTreatmentCardiac Output, Low1
3CompletedTreatmentMitral Valve Insufficiency / Pulmonary Hypertension (PH)1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Low Cardiac Output Syndrome / Pulmonary Edemas / Shock, Cardiogenic1
4RecruitingTreatmentProphylaxis of cardiomyopathy / Shock, Septic1
Not AvailableCompletedPreventionComplication of Extracorporeal Circulation / Kidney Circulation Disorder / Renal Function Disorder1
Not AvailableCompletedTreatmentAcute Kidney Injury (AKI)1
Not AvailableCompletedTreatmentAortic Valve Stenosis / Heart Failure, Diastolic / Physiologic Monitoring / Physiology1
Not AvailableCompletedTreatmentCongenital Cardiovascular Defects / Low Cardiac Output Syndrome1
Not AvailableCompletedTreatmentHepatectomy1
Not AvailableRecruitingNot AvailableHeart Failure, Unspecified1
Not AvailableRecruitingPreventionArterial Hypotension1
Not AvailableTerminatedTreatmentPersistent Fetal Circulation Syndrome / Persistent Pulmonary Hypertension of Newborn (PPHN)1

Pharmacoeconomics

Manufacturers
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp anesthesia critical care
  • Bedford laboratories div ben venue laboratories inc
  • Bioniche pharma usa llc
  • Claris lifesciences ltd
  • Gland pharma ltd
  • Hospira inc
  • International medicated systems ltd
  • B braun medical inc
  • Baxter healthcare corp
  • Bedford laboratories
  • Hikma farmaceutica (portugal) sa
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous1 mg/mL
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous10 mg/10mL
Injection, solutionIntravenous20 mg/20mL
Injection, solutionIntravenous50 mg/50mL
Injection, solutionIntravenous.2 mg/mL
Injection, solutionIntravenous200 ug/mL
SolutionIntravenous1.0 mg
SolutionIntravenous1 mg
Prices
Unit descriptionCostUnit
Primacor 0.2 mg/ml-d5w 100 ml1.6USD ml
Milrinone-d5w 20 mg/100 ml1.45USD ml
Milrinone lact 20 mg/20 ml vial1.44USD ml
Milrinone lact 10 mg/10 ml vial1.31USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)>300 °CPhysProp
water solubilitySlightly solubleNot Available
logP0.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.209 mg/mLALOGPS
logP1.04ALOGPS
logP0.33ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)7.54ChemAxon
pKa (Strongest Basic)4.82ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area65.78 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity61.14 m3·mol-1ChemAxon
Polarizability21.46 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9807
Caco-2 permeable+0.6889
P-glycoprotein substrateNon-substrate0.8041
P-glycoprotein inhibitor INon-inhibitor0.7835
P-glycoprotein inhibitor IINon-inhibitor0.9799
Renal organic cation transporterNon-inhibitor0.8614
CYP450 2C9 substrateNon-substrate0.7016
CYP450 2D6 substrateNon-substrate0.8411
CYP450 3A4 substrateNon-substrate0.5641
CYP450 1A2 substrateInhibitor0.5399
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9816
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8827
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7866
Ames testNon AMES toxic0.7822
CarcinogenicityNon-carcinogens0.9351
BiodegradationNot ready biodegradable0.993
Rat acute toxicity2.5820 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.991
hERG inhibition (predictor II)Non-inhibitor0.8941
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0090000000-1894d0a48fc2ccb74718
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0190000000-6ae34a9fd604b709bcc9
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0970000000-c1a7f68e4f0eb27d6881
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-1900000000-8e2c336e4e2425cca486
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-3900000000-047756d13498358fc54d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-01ta-1910000000-c2df049a2cac6a6ad313
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-03dj-3910000000-21cb0ac7a539590cf3a5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-08n9-7900000000-f774999fc6fb39238858
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00o1-9300000000-9b1eed78c20489183326
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-004l-9100000000-c84b782dfa6c28c15ddc
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-001i-0900000000-969f8d74389284d0c167
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0790000000-fe6863cad241275fc104

Taxonomy

Description
This compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Bipyridines and oligopyridines
Direct Parent
Bipyridines and oligopyridines
Alternative Parents
3-pyridinecarbonitriles / Methylpyridines / Hydroxypyridines / Heteroaromatic compounds / Nitriles / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Bipyridine / 3-pyridinecarbonitrile / Methylpyridine / Hydroxypyridine / Heteroaromatic compound / Azacycle / Nitrile / Carbonitrile / Organic nitrogen compound / Organic oxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
nitrile, pyridone, bipyridines (CHEBI:50693)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
Gene Name
PDE3A
Uniprot ID
Q14432
Uniprot Name
cGMP-inhibited 3',5'-cyclic phosphodiesterase A
Molecular Weight
124978.06 Da
References
  1. Cone J, Wang S, Tandon N, Fong M, Sun B, Sakurai K, Yoshitake M, Kambayashi J, Liu Y: Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol. 1999 Oct;34(4):497-504. [PubMed:10511123]
  2. Kuthe A, Magert H, Uckert S, Forssmann WG, Stief CG, Jonas U: Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur Urol. 2000 Jul;38(1):108-14. [PubMed:10859452]
  3. Lefievre L, de Lamirande E, Gagnon C: Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable complex with calmodulin, and PDE3A in human spermatozoa. Biol Reprod. 2002 Aug;67(2):423-30. [PubMed:12135876]
  4. Zhang W, Ke H, Colman RW: Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. Mol Pharmacol. 2002 Sep;62(3):514-20. [PubMed:12181427]
  5. Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J, Yoshitake M, Liu Y: Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther. 2002 Sep;16(5):417-27. [PubMed:12652111]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on January 14, 2018 10:04